Serum Osteopontin and its Relation to Colorectal Carcinoma in Egyptian Patient

Abstract

Abstract Background Colorectal cancer had a low incidence several decades ago. However, it has become a predominant cancer and now accounts for approximately 10% of cancer-related mortality in western countries. The ‘rise’ of colorectal cancer in developed countries can be attributed to the increasingly ageing population, unfavourable modern dietary habits and an increase in risk factors such as smoking, low physical exercise and obesity. Objectives The aim of this study to evaluate the role of serum level of osteopontin in prediction of Colorectal Carcinomain in correlation with tissue histopathology which it is the gold standard test in Egyptian patient. Patients and Methods The study was a Randomized controlled clinical trial. Which is a prospective, random, clinical trial conducted at Ain Shams University Hospitals at endoscopic unit on patients who refered for colonscopy. This study was conducted on 80 patients who were divided into 2 groups: Group A: 40 patients diagnosed as Colorectal Carcinoma as a patient group, Group B: 40 patients with age and sex matched control group who have normal colonscopy. Results There was statistically significant difference between CRC patients and normal colonscopic patients regarding the level ofosteopontin being higher in CRC patients (P value = 0.000). Also ROC curve for osteopontin in prediction of CRC showed the best cut of value >12 ng/ml with area under the curve (AUC) = 0.889, sensitivity =85%, specificity =77.5% with positive predictive value =79.1% Conclusion Serum Osteopontin (OPN) level is higher in patients with CRC than patients with normal colonscopy, so it can be used as a diagnostic marker for HCC.